EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

The effects of Givinostat for Duchenne muscular dystrophy: a systematic review

Carolina de Oliveira Cruz Latorraca, Bruna Carolina de Araújo, Camila Monteiro Cruz, Cinara Stein, Isabela Porto de Toledo, Mylena Maria Guedes de Almeida, Patrícia do Carmo Silva Parreira, Rafael Leite Pacheco, Roberta Borges Silva, Verônica Colpani, Rachel Riera

HTA Journal · 31.10.2026 · 1 (2) · 59-69

DOI: 10.67516/htaj.26.2.59 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift HTA Journal, online erschienen am 31.10.2026. Verfasst von Carolina de Oliveira Cruz Latorraca und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Givinostat, a histone deacetylase inhibitor, has been investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and slow muscle degradation. DMD is a genetic neuromuscular degenerative disease that begins in early childhood. It is an X-linked recessive disorder characterized by mutations in the dystrophin gene and progressive and severe muscle weakness and atrophy are the main characteristics of this disease. DMD predominantly affects boys, while most females are asymptomatic carriers, with a global prevalence estimated at 19.8 cases per 100,000 live male births.

Objective

To evaluate the efficacy and safety of Givinostat for individuals with DMD based on evidence from randomized controlled trials (RCTs). Methodology: We conducted a systematic review following PRISMA guidance, focusing on RCTs assessing Givinostat versus placebo, standard care, no treatment, or any active pharmacological intervention in DMD. CENTRAL, MEDLINE, Embase, PEDro and LILACS were searched (August 2025) without restrictions. Two reviewers independently selected studies, extracted data, and appraised risk of bias using the original Cochrane tool. Certainty of evidence was assessed using GRADE. The protocol was prospectively registered in the PROSPERO database (CRD420251107551).

Results

Two RCTs were included, although one is still ongoing. EPIDYS (n=179) compared Givinostat (13 mg to 47 mg twice daily) with placebo for 72 weeks. There is uncertainty regarding the effects of Givinostat on global symptom assessment (mean difference [MD] 1.91; 95% CI 0.30 to 3.53; n=120; very low certainty), serious adverse events (risk ratio [RR] 2.07; 95% CI 0.45 to 9.44; n=179; very low certainty), functional capacity assessed by two different instruments (n=120; very low certainty), and quality of life (MD 3.70; 95% CI −2.30 to 9.70; n=120; very low certainty). Givinostat may have little or no effect on the risk of any adverse events (RR 1.02; 95% CI 0.94 to 1.10; n=179; low certainty).

Conclusions

Current evidence on the efficacy of Givinostat remains uncertain, while it may have little or no effect on the risk of any adverse events. Further well-designed RCTs with larger sample sizes and varying disease stages are needed to reduce these uncertainties.

Zitieren

APA

Latorraca, C. D. O. C., Araújo, B. C. D., Cruz, C. M., Stein, C., Toledo, I. P. D., Almeida, M. M. G. D., Parreira, P. D. C. S., Pacheco, R. L., Silva, R. B., Colpani, V., & Riera, R. (2026). The effects of Givinostat for Duchenne muscular dystrophy: a systematic review. HTA Journal, 1(2), 59-69. https://doi.org/10.67516/htaj.26.2.59

Vancouver

Latorraca CDOC, Araújo BCD, Cruz CM, Stein C, Toledo IPD, Almeida MMGD, et al. The effects of Givinostat for Duchenne muscular dystrophy: a systematic review. HTA Journal. 2026;1(2):59-69. doi:10.67516/htaj.26.2.59

BibTeX
@article{Latorraca2026,
  author = {Latorraca, Carolina de Oliveira Cruz and Araújo, Bruna Carolina de and Cruz, Camila Monteiro and Stein, Cinara and Toledo, Isabela Porto de and Almeida, Mylena Maria Guedes de and Parreira, Patrícia do Carmo Silva and Pacheco, Rafael Leite and Silva, Roberta Borges and Colpani, Verônica and Riera, Rachel},
  title = {The effects of Givinostat for Duchenne muscular dystrophy: a systematic review},
  journal = {HTA Journal},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {59--69},
  doi = {10.67516/htaj.26.2.59}
}
Kostenlos starten →